STEM CELL Therapy thru Laminine_Part-1(new link)
STEM CELL Therapy thru laminine_part1new link. Uploaded by cabmon0001 on Mar 14 2013. cabmon 0001.

By: cabmon0001

Read more from the original source:
STEM CELL Therapy thru Laminine_Part-1(new link) - Video

2013 Stem Cell Therapy #1
Introduction to 11 weeks of stem cell therapy in Delhi with Dr Geeta Shroff.

By: Louis Rowe

Follow this link:
2013 Stem Cell Therapy #1 - Video

Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy
Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy He is a known case of Myotonic MD with history of gradual onset of progressive lower extremities muscle weakness since age of 25 years. He also has history of delayed milestones. His weakness is progressive in nature. He falls while walking so walks with human support only. He has complaints of early fatigue and slurred speech due to tongue hypertrophy. He has atrophy of proximal muscles of all extremities. He has modified independence in almost all ADL. Neurologically, hypotonic, hyporeflexic. On examination: lower limb distal muscles are 0/5 on MMT while proximal muscles are having 2++/5 on MMT. Upper extremities left side proximal muscles are 1++/5 while right side proximal muscles are 3 #713;/5, distal muscles are 3++/5 in upper extremities. Functionally, modified independence in all ADL. On FIM he scores 99. After Stem Cell Treatment 1. His face looks more fresh. 2. His neck used to fall back previously but now he can control his neck well in each movement. 3. Back muscle strength has improved. 4. Bridging is better now. He can lift his back more up now which he couldn #39;t do at all. 5. His stamina has improved. 6. His shoulder strength has improved. Shoulder shrugging is better now. Active shoulder flexion, range of motion is more now. 7. Side lying to sitting he can do without any support which was not possible before. 8. Drooling of saliva from mouth in night is completely stopped. 9. His legs used ...

By: neurogenbsi

Visit link:
Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy - Video

Durham, N.C. People with heart disease have more treatment options than ever. However, sometimes nothing gets rid of continued chest pain known as angina. Researchers say they are looking at a special stem cell therapy to help those patients.

Danny Darden, 49, has heart disease and frequent chest pain despite two years worth of every treatment, surgery and medication available to stop it.

If I walk around the block, I give out and have chest pains, he said.

Duke cardiologist Dr. Tom Povsic included Darden in a phase 3 trial looking for benefits of a special stem cell therapy to stimulate the growth of new vessels feeding blood to the heart.

In certain patients, the arteries can no longer be fixed, or bypass surgery can't be used to fix the arteries. And in those patients, novel therapies are sorely needed, Povsic said. So, the stem cells in this particular case are obtained from the patient themselves.

The cells, originating in the bone marrow, are stimulated and released into the blood stream, extracted and then administered directly into the heart through a special catheter.

Last week, I was injected with the stem cells, Darden said. I'm excited to be in it, because I feel it's going to work, and even if it (doesnt) work for me, it's going to work for other people.

The study is blind, meaning Darden may have received a fake infusion. Participants are followed for two years. A smaller previous study showed promising results.

The benefit that was seen in the early study far exceeds what was seen with many medicines that are approved for angina relief, Povsic said.

Researchers say if the stem cell therapy benefits are confirmed in patients with angina, it could also be studied in patients dealing with stroke, heart attack or heart failure.

Here is the original post:
Duke doctor: Stem cell therapy might help heart disease patients

Manila: A Philippine-based group has aired concern over the dangers of stem cell treatment as it warned of the possibility that materials being used for such procedures could have been extracted from hapless donors, particularly human foetuses.

Dr Leo Olarte, spokesman of the Philippine Society for Stem Cell Medicine, said they were alarmed over reports coming locally and from abroad that some stem cell materials were being taken from the unborn.

At the same time he called on the Department of Health to carefully watch stem cell treatment practitioners. The Catholic Church, he said, should unite with health practitioners and put an end to such practices.

Olarte was quoted as saying in reports that allogenic stem cells from aborted foetuses of humans were being exported to the Philippines.

Article continues below

We cannot stand by and merely watch how they exploit people in poverty just to profit while allowing others who are economically well off to benefit from this, he said.

He said there were reports that human stem cells from foetuses and female egg cells were being used in anti-ageing procedures and other medical treatments.

Olarte is also concerned over the sale of supposedly stem cell products that come in the form of injectibles and even soaps.

Dont patronise those products. An example is the stem cell soap. It is unfair that stem cell therapy becomes a quackery, he said.

Earlier, Department of Health Secretary Enrique Ona led a national convention participated in by doctors to discuss the truth behind stem cell therapy.

Originally posted here:
Philippine-based group warns on stem cell medicine

Beckers Muscular Dystrophy Improvement After Stem Cell Therapy in Mumbai India
He is a known case of BMD since 10 years (2003). The difficulty initially started as difficulty in walking and stair climbing. Slowly weakness progressed and he could not get up from the floor. He went to the local doctor, who advised him to get investigations done. Investigations in 2005 showed Becker #39;s specific gene deletion, however diagnosis was confirmed as BMD based on clinical symptoms, increased CPK values and EMG changes that were consistent with BMD. On examination, he is hypotonic and hyporeflexic. There is hypertrophy of calf muscles and wasting of quadriceps and trunk muscles. There is slight tongue hypertrophy and slight difficulty in speech. He has complete passive range of motion. His upper extremities strength is above functional grade and he does the overhead activities. Out of all the antigravity muscles of lower limbs only plantar flexors are above functional level. Hip flexors are functional level and all the other lower extremities muscles are below functional level. Abdominals have functional level strength. Bilateral extremities are profoundly weak. Functionally he is independent in all ADL, however has great difficulty in getting up from lower surfaces. He needs support to climb staircase. On FIM he scores 104. After Stem Cell Treatment 1. Bilateral calf firmness has become softer than before. 2. He can now do supine to sit independently with ease, earlier he used to take strain and get up. 3. He can do sit to supine with ease than before. 4 ...

By: neurogenbsi

Here is the original post:
Beckers Muscular Dystrophy Improvement After Stem Cell Therapy in Mumbai India - Video

Stem Cell Therapy Webinar with Dr. Kamau Kokayi at Patients Medical
Join us as Dr. Kamau Kokayi, Director of Cell Technologies at the New York Stem Cell Treatment Center at Patients Medical in NYC explains what Adipose Derived Stem Cell Therapy is and what types of medical conditions Dr. Kokayi and his team of researchers are enrolling for the clinical trial.

By: PatientsMedicalNYC1

Read the original post:
Stem Cell Therapy Webinar with Dr. Kamau Kokayi at Patients Medical - Video

Pet Surgery | Las Vegas | Veterinary Stem Cell Therapy | TPLO
veterinary-stemcell.com 702-250-1888 What is stem cell therapy? Stem cells are the body #39;s repair cells. They have the ability to divide and differentiate into many different types of cells based on where they are needed throughout the body. Stem cells can divide and turn into tissues such as skin, fat, muscle, bone, cartilage, and nerve to name a few. They even possess the ability to replicate into organs such as the heart, liver, intestines, pancreas, etc. Call Dr. Mauer or visit his site today.. Find out if stem cell therapy is right for your pet.

By: Roger Mauer

Read more:
Pet Surgery | Las Vegas | Veterinary Stem Cell Therapy | TPLO - Video

Stem Cell Patient Treated With Adult Stem Cell Therapy - Video
Sigrid Zipser, a patient with coronary artery disease and congestive heart failure and no more treatment options seeked out treatment with Vescell stem cell therapy because it was treatment with her own adult stem cells. Producer: VesCell; Creative Commons license: Attribution.

By: rosaryfilms

Read the original here:
Stem Cell Patient Treated With Adult Stem Cell Therapy - Video - Video

SAN DIEGO, Jan. 31, 2013 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that the Company was granted 20 patents worldwide in 2012, eight U.S. and twelve foreign. These patents bolster the Company's already strong proprietary position for its ground-breaking diabetes product, VC-01, as well as other applications of its broad technology platform.

(Logo: http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a)

VC-01 is a very promising, development-stage product that consists of pancreatic precursor cells (called PEC-01) derived from a proprietary human embryonic stem cell line and encapsulated in a proprietary, immune isolating medical device (the ENCAPTRA device). When implanted under the skin in suitable animal models, the cells further differentiate into insulin producing and other endocrine cells that regulate blood glucose in a manner similar or identical to a normal pancreas. If VC-01 performs in humans as it has in animal studies, it could effectively cure type 1 diabetics and be an important new therapy for insulin dependent type 2 diabetics.

ViaCyte's significant intellectual property portfolio now includes over 300 issued patents and pending applications related to the growth, directed differentiation and use of human pluripotent stem cells such as human embryonic stem cells and induced pluripotent stem cells. This portfolio includes 51 issued U.S. and foreign patents specifically directed to the Company's VC-01 product. In addition to the protection afforded by patents, the Company also relies on significant proprietary know-how to develop its product offerings.

Dr. Paul Laikind, ViaCyte's president and chief executive officer said, "Our comprehensive and growing intellectual property portfolio helps to establish us as a leading company in the cell therapy and regenerative medicine field. Although the Company's resources are currently fully committed to the rapid development of VC-01 as a potentially transformative treatment for patients with insulin-dependent diabetes, our platform technology has many other important applications."

In July and August of 2012, the Board of Patent Appeals and Interferences of the U.S. Patent and Trademark Office (the "Board") also issued two decisions favoring ViaCyte on motions filed in the patent interference proceedings between ViaCyte and Geron Corporation (Menlo Park, California). The interferences involved ViaCyte's U.S. Patent No. 7,510,876 ("876 Patent"), which is directed to human definitive endoderm cell cultures in vitro. The Board upheld the claims of ViaCyte's '876 Patent in its entirety over Geron's applications. In September 2012, Geron appealed this decision in the United States District Court for the Northern District of California.

About ViaCyteViaCyte, a private company that has emerged as a leader in the field of regenerative medicine, is currently focused on developing a novel cell therapy for the treatment of diabetes. The Company's lead product is based on the production of pancreatic progenitors derived from human pluripotent stem cells. These cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells secrete insulin and other regulatory factors in response to blood glucose levels. ViaCyte's goal for this potentially transformative diabetes product is long term insulin independence without immune suppression, and without risk of hypoglycemia and other diabetes-related complications.

ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.

Excerpt from:
ViaCyte's Role as a Leading Cell Therapy Company Bolstered with the Issuance of 20 Patents in 2012

Trachea regenerated using stem cell therapy
An interview with the President of Harvard Bioscience, who played a key role in the regeneration of the trachea which was implanted at the time of surgical resection of tumorous trachea using the patient #39;s own stem cells. The uploaded video is not the property of Stemade Biotech Pvt. Ltd. ("the Company"), and the Company shall not be held responsible for the authenticity and accuracy of information presented in this video.From:StemadeBiotechViews:0 0ratingsTime:07:55More inScience Technology

More:
Trachea regenerated using stem cell therapy - Video

Stem Cell Therapy for Animals Q A at Animal Clinic of
- Captured Live on Ustream at http://www.ustream.tvFrom:HawaiiWellnessDirViews:1 0ratingsTime:39:36More inPeople Blogs

View post:
Stem Cell Therapy for Animals Q

Alan Fine on Advances in stem cell therapy
Alan Fine, Professor of Medicine, Director Stem Cell Biology Program, Boston University Alan Fine spoke at the Expert Exchange Roundtable on Pushing the boundaries of longevity, 9 September 2011, sSwissnex Boston, Cambridge, Massachusetts, USAFrom:swissretvViews:12 0ratingsTime:01:18:35More inEducation

Excerpt from:
Alan Fine on Advances in stem cell therapy - Video

MissouriCuresEvents_Oct2012_Dr.MarieCsete
"The stem cell therapy race: roadblocks to the finish line", as presented by Dr. Marie Csete at The Danforth Center on behalf of Missouri Cures Education Foundation #39;s Speaker Series in October, 2012.From:MissouriCuresEventsViews:1 0ratingsTime:51:36More inNonprofits Activism

Read more:
MissouriCuresEvents_Oct2012_Dr.MarieCsete - Video

Robert Toves Testimonial (Parkinson #39;s Disease) Stem Cell Therapy
Robert Toves is a patient at Integra Medical Center, Mr.Toves suffers of Parkinson #39;s disease and has come to try Dr.Gonzalez method of stem cell therapy, just less than an hour after the stem cell therapy great results seem to show.From:OmarGonzalezMDViews:1 0ratingsTime:05:58More inScience Technology

Read more here:
Robert Toves Testimonial (Parkinson's Disease) Stem Cell Therapy - Video

Stem Cell Therapy - Let Your Own Stem Cells Make Wrinkles Virtually Disappear! Free postage
Stem Cell Therapy - Let Your Own Stem Cells Make Wrinkles Virtually Disappear!From:Deals2uTVViews:0 0ratingsTime:02:01More inHowto Style

See the rest here:
Stem Cell Therapy - Let Your Own Stem Cells Make Wrinkles Virtually Disappear! Free postage - Video

Making Stem Cell Thearpy Safer - Mayo Clinic
Mayo Clinic researchers have found a way to detect and eliminate potentially troublemaking stem cells to make stem cell therapy safer. Induced Pluripotent Stem cells, also known as iPS cells, are bioengineered from adult tissues to have properties of embryonic stem cells, which have the unlimited capacity to differentiate and grow into any desired types of cells, such as skin, brain, lung and heart cells. Study Author, Dr. Timothy Nelson provides and overview.From:mayoclinicViews:45 0ratingsTime:02:04More inScience Technology

See the rest here:
Making Stem Cell Thearpy Safer - Mayo Clinic - Video

NEW YORK, Nov. 26, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy industry, today announced that Company management has been invited to present at the Piper Jaffray 24th Annual Healthcare Conference.

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information on NeoStem, please visit http://www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Here is the original post:
NeoStem to Present at Piper Jaffray 24th Annual Healthcare Conference

Introducing Stem Cell Therapy Using Oral Placenta Stem Cells | Stem Cell Malaysia
stemcellmalaysia.com Stem cell therapy can take on various forms and choices. Due to the advent of technology, stem cell therapy using oral placenta stem cells is now available. For more information on stem cell therapy, please visit Stem Cell Malaysia at stemcellmalaysia.comFrom:stemcells2012Views:3 1ratingsTime:05:23More inScience Technology

Continue reading here:
Introducing Stem Cell Therapy Using Oral Placenta Stem Cells | Stem Cell Malaysia - Video

What Are Stem Cells and Stem Cell Therapy Stemenhance
http://www.stemcellproduct.net This video gives you the definition, facts, and understanding on what are stem cells, that there are two of them embryonic and adult stem cells, how they work and the uses of stem cell when the tissue is affected in your body and how messengers signal the bone marrow to release adult stem cells to help in the repair of the injured tissue. Why this information is exciting for me to do a video is because I see stemcells as the best way of how to produce optimal health in your body. The way I look at it is that optimal health equals the number of healthy cells in your body and the only way the body repairs a damaged area is by creating and sending adult stem cells to that area. That #39;s why I #39;m introducing a stem cell product from a nutrition company who patented a stem cell enhancer which supports the release of adult stem cells. What will also excite you too is that Stemtech (the stemcell company) has also come out with two other products that will also optimize the circulation of these stem cells and other nutrients and aid in the ability for them to move and migrate into the affected tissue where they can transform and duplicate into fresh, healthy new cell tissue. So in my eyes having products like these will help anyone in my pursuit of health and wellness. I know it #39;s helping me strengthening my cells in my body after being diagnosed with chronic fatigue syndrome 20 plus years ago because I know how important nutrition and cell help to gain my ...From:Jennifer MarksViews:1 0ratingsTime:06:37More inHowto Style

View original post here:
What Are Stem Cells and Stem Cell Therapy Stemenhance - Video